Advice
following a full submission
botulinum toxin type A (BOTOX®) is accepted for restricted use within NHS Scotland.
Indication under review: The management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency.
SMC restriction: Patients who have failed appropriate oral treatment options.
In two phase III double-blind studies, botulinum toxin type A (BOTOX®) significantly reduced the mean daily number of urinary incontinence episodes compared with placebo.
Download detailed advice179KB (PDF)
Medicine details
- Medicine name:
- botulinum toxin type A (Botox)
- SMC ID:
- 931/13
- Indication:
- The management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency.
- Pharmaceutical company
- Allergan Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 July 2014